GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

SRI International Recipient of $56.9M from the NIAID

  • SRI International has been awarded a $56.9-million contract from the NIAID to provide preclinical services for the development of drugs and antibodies for anti-infective therapeutics.

    SRI will support the development of treatments for avian flu, SARS, West Nile virus, hepatitis, and biodefense pathogens and toxins for five years. The company will perform medicinal chemistry, custom drug synthesis, formulation, analytical chemistry, clinical manufacturing, microbiology and virology screening, pharmacokinetics, safety testing, and preparation of IND applications to the FDA.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?